Eli Lilly and Co (NYSE:LLY)

371.95
Delayed Data
As of 4:00pm ET
 +3.41 / +0.93%
Today’s Change
231.87
Today|||52-Week Range
375.25
+34.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$356.1B

Company Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Contact Information

Eli Lilly & Co.
Lilly Corporate Center
Indianapolis Indiana 46285
P:(317) 276-2000
Investor Relations:
(317) 277-1838

Employees

Shareholders

Mutual fund holders41.19%
Other institutional32.60%
Individual stakeholders11.65%

Top Executives

David A. RicksChairman, President & Chief Executive Officer
Anat AshkenaziChief Financial Officer & Senior Vice President
Daniel M. SkovronskyChief Scientific Officer & Senior Vice President
Diogo RauSenior VP, Chief Information & Digital Officer
Alonzo WeemsSenior VP, Chief Ethics & Compliance Officer